NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP
Bio-techne Corp. TECH
17 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
$1.2B
▲ 5.2% vs FY2023
EPS · FY24
$0.46
Dividend / sh · FY24
$0.32
Payout · FY24
69%
ROE · FY24
3.5%
Net margin · FY24
6.0%
Dividend coverage
1.4×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 1.2B
Revenue, FY2024 · full 17-year series below
Revenue
Net income
6 cents of every revenue dollar became profit this year.
Per share
USD 0.46
Diluted EPS, FY2024
EPS
Dividend
Earnings covered the dividend 1.4 times — the rest stayed in the company.
Profitability
3.5%
Return on equity, FY2024
ROE
Operating margin8.4%
Net margin6.0%
Return on assets2.8%
Each USD of equity produced 4 cents of profit this year.
Returned to shareholders
USD 274.4M
returned in FY2024 · dividends + net buybacks
Dividends paidUSD 50.4M
Net buybacksUSD 224.0M
Share of profit373.8%
Consecutive raises—
USD 50.4M in dividends and USD 224.0M in buybacks — 374% of the year's profit, so the payout drew on cash built up earlier.
Growth
+10.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+3.3%
+10.5%
+10.4%
+10.6%
Net income
−35.4%
−20.4%
−3.8%
−2.6%
EPS, diluted
−34.8%
Dividend / share
+0.0%
Returned to shareholders
+27.0%
+41.2%
+19.3%
+12.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.15B
Shares outstanding, FY2024
Change, 5 years+4.6%
Change, 10 years+4.9%
The share count grew 5% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 2.6B
total assets, end of FY2024
Total assetsUSD 2.6B
CashUSD 162.2M
Gross debtUSD 346.0M
Net debtUSD 183.8M
Current ratio3.46×
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Revenue $B
1.2
1.2
1.1
1.1
0.9
0.7
0.7
0.6
0.6
0.5
0.5
0.4
0.3
0.3
0.3
0.3
0.3
Operating income $B
0.1
0.2
0.3
0.3
0.2
0.2
0.1
0.1
0.1
0.2
0.1
0.2
0.0
0.2
0.2
0.2
0.2
EBITDA $B
0.2
0.3
0.4
0.4
0.3
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.0
0.2
0.2
0.2
0.2
Income tax $B
0.0
0.0
0.1
0.0
0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.1
0.0
0.0
0.1
0.0
0.1
Net income $B
0.1
0.2
0.3
0.3
0.1
0.2
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
EPS, diluted $
0.46
1.05
1.76
1.66
0.87
5.82
2.47
3.31
2.03
2.80
2.89
3.00
3.05
3.04
3.02
2.94
2.78
Dividend / sh $
0.32
0.32
0.32
0.32
0.32
1.28
1.28
1.28
1.28
1.28
1.27
1.23
1.18
1.11
1.07
1.03
0.75
Payout %
69
30
18
18
35
21
50
38
62
46
44
41
39
37
35
35
27
ROE %
3.5
8.3
15.6
16.7
9.5
18.0
8.6
12.4
8.3
12.1
13.1
14.5
15.9
17.8
20.6
22.9
23.1
Shares out B
0.15
0.16
0.16
0.16
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.04
0.04
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
66 of 66
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed